The notices it replaced
- Reissues: PAR-17-318 NCCIH Natural Product Phase I-IIa Clinical Trial Award (R33)
- 2 steps back: PAR-16-419 Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R33)
- 3 steps back: RFA-AT-16-002 Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R33)
Replaced by PAR-20-217.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,100,200 in first-year total cost, median $550,100.
Most frequent study sections
- Special Emphasis Panel[ZAT1 SM (54)]1
- Special Emphasis Panel[ZAT1 YW (01)]1
Most frequent institutions
- IMMUNOGENICS, LLC1
- LOUISIANA STATE UNIV HSC SHREVEPORT1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Optimization of Blood Levels of 25(OH)-vitamin D in African Americans1R33AT010637-01A1 | JAIN, SUSHIL K | LOUISIANA STATE UNIV HSC SHREVEPORT, LA | $507,204 | ZAT1 |
| 2017 | Latiglutenase as a Treatment for Celiac Disease1R33AT009637-01 · under PAR-16-419 | MURRAY, JOSEPH ASYAGE, JACK A. | IMMUNOGENICS, LLC, CA | $592,996 | ZAT1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.